Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Severe Unprofitability ⢠Negative Cash Flow ⢠Share Dilution GRAL faces a high-risk investment profile due to extreme losses, persistent cash burn, rapid dilution, and a demanding valuation despite strong headline liquidity.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend weakening ⢠Key support ⢠Heavy resistance Support Level: $76â$76.60 Resistance Level: $79â$80.60 GRAL remains above its short-term average but is pulling back from $82.50, so watch $76 support and $79â$80.60 resistance for the next directional move.
Sentiment & News
Key News Insights: ⢠FDA Catalyst ⢠Trial Uncertainty ⢠Institutional Buying GRAIL's outlook hinges on the upcoming FDA review of Galleri, with growth and institutional buying offset by weak trial results, delay risks, and insider selling.
AI Summary
GRAL is now a binary FDA-and-reimbursement bet: Galleri clearance could unlock adoption upside, but the failed NHS trial, deeply negative cash flow, and likely dilution make the stock vulnerable if clinical utility or payer support remains limited.
Description
GRAIL, Inc. is a biotechnology firm based in Menlo Park, California, established in 2015. The company develops blood-based tests intended to detect cancer at early stages in asymptomatic individuals and to support faster diagnostic resolution when cancer is suspected, as well as tests for minimal residual disease and other post-diagnostic uses. GRAIL previously operated as a subsidiary of Illumina, Inc.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 26 | Dec 3 | GRAL | GRAIL, Inc. | Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside. | Closed | -8.1% |